搜索结果
靶点ID:TCMBANKGE012726
靶点别名:ABL; MTP
靶点描述:microsomal triglyceride transfer protein
染色体:4
染色体位置:4q23
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:7467
OMIM_Link:157147
Ensembl_Link:ENSG00000138823
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN036851 | chenodeoxycholic acid | (3alpha,5beta,7alpha,8xi)-3,7-dihydroxycholan-24-oic acid; 3-alpha,7-alpha-Dihydroxycholanic acid; Anthropodesoxycholic acid; SMP1_000064; 7-alpha-Hydroxylithocholic acid; BSPBio_000190; Spectrum5_002009; JN3; CDCA; Acide chenodeoxycholique [INN-French]; Acidum chenodeoxycholicum [INN-Latin]; (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 3-alpha,7-alpha-Dihydroxycholansaeure [German]; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)- (9CI); (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; Chenodesoxycholsaeure [German]; 5.BETA.-CHOLANIC ACID-3.ALPHA., SODIUM SALT; AIDS-045143; CCRIS 2195; Gallodesoxycholic acid; AIDS045143; Chenodiol (USAN); Chenix (TN); Chenix; 7alpha-hydroxylithocholic acid; SODIUM URSO; Prestwick1_000285; Chenic acid; 5-beta-Cholan-24-oic acid, 3-alpha,7-alpha-dihydroxy-; HSCI1_000210; D00163; chenodeoxycholicacid; Cholan-24-oic acid, 3,7-dihydroxy-, (3-.alpha., 5-.beta., 7-.alpha.)-; Chenodiol [USAN]; Anthropododesoxycholic acid; SPBio_002409; Prestwick0_000285; Anthropodeoxycholic acid; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)-; Chenodeoxycholic acid (JP15/INN); Chenodiol; NSC681066; CHEBI:16755; 474-25-9; Chenodeoxycholic acid; NSC-681066; 3-alpha,7-alpha-Dihydroxy-5-beta-cholan-24-oic acid; SBB002935; BPBio1_000210; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Prestwick2_000285; Acido chenodeoxicholico [INN-Spanish]; LMST04010032; Chendol; C02528; EINECS 207-481-8; Prestwick3_000285; NSC 657949 | C24H40O4 | 392.57 | CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C |
| TCMBANKIN058151 | taxifolin | (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-chromanone; (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone; (2R,3R)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 20254-28-8 (DELETED); trans-Dihydroquercetin; ()-Taxifolin; Taxifolin; ZINC00105077; CHEBI:17948; AIDS003061; MEGxp0_000741; 17654-26-1 (DELETED); 3,3′,4′,5,7-Pentahydroxyflavanone; (+)-Taxifolin; MLS000759539; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chroman-4-one; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; 78666_FLUKA; MLS001074712; STOCK1N-51590; DQH; T4512_SIGMA; TAXIFOLIN-(+); (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; ACon1_000239; (+)-Dihydroquercetin; SMR000466389; 480-18-2; C01617; (2R,3R)-TRANS-DIHYDROQUERCETIN; MLS001066341; AIDS-003061; MLS000759526; AC1LEHLM; NC00093; TAXIFOLIN-(+/-); SCHEMBL1707803; ZINC105086; MLS001423978; (?)-Epitaxifolin; ZB003534; CHEMBL221328; (2R,3S)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-chromen-4-one; (2R,3S)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one; Dihydro quercetin; SMR000499525; CCG-100843; CPD000499525; CHEBI:75747; (-)-epitaxifolin; SAM001246760; AB00698321-05; AJ-11152; HMS2051I06; dihydroquercetin ; (2R,3S)-epitaxifolin; MLS000759526; dihydroquercetin | C15H12O7 | 304.25 g/mol | C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O |
| TCMBANKIN061606 | Silibinin | 7C3MT; NSC 651520; (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-7-yl]-4-chromanone; Silybin (7CI); AC-6081; MEGxp0_001301; Silybine; BC216320; Spectrum3_001132; AIDS-003063; SDCCGMLS-0066916.P001; 4H-1-Benzopyran-4-one, 2-[(2R,3R)-2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; SMP2_000323; KBio3_002123; 3,5,7-Trihydroxy-2-(3-(4-hydroxy-3-methoxyphenyl)- 2-(hydroxymethyl)-1,4-benzodioxan-6-yl)-4-chromanone; Silibinin [INN]; AIDS003063; silybin; ZINC21992919; 3,5,7-Trihydroxy-2-(3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxan-6-yl)-4-chromanone; Spectrum2_001694; BB_NC-1044; NCGC00091057-01; Silibinina [INN-Spanish]; NSC651520; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-3,5,7-trihydroxy-, (2R-(2-alpha,3-beta,6(2R*,3R*)))-; EINECS 245-302-5; (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-methylol-2,3-dihydro-1,4-benzodioxin-7-yl]chroman-4-one; Spectrum5_001893; Flavobin Spofa; SPECTRUM1505256; 4H-1-Benzopyran-4-one, 2-(2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-, (2R-(2alpha,3beta,6(2R*,3R*)))-; Silibininum [INN-Latin]; Silibinine [INN-French]; Silymarin I; (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-7-yl]chroman-4-one; ZINC02033589; Silliver; Flavobin; Silymarine I; KBioGR_002481; (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-7-yl]chroman-4-one; AKOS015965310; Spectrum4_001978; SPBio_001648; BSPBio_002623;SILYBIN | C25H22O10 | 482.44 g/mol | COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000035 | Digestive System Diseases; Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI000061 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000071 | Digestive System Diseases; Chemically-Induced Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000294 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI002287 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | group | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI004674 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI004958 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI006103 | - | - | Neoplastic Process | disease | |
| TCMBANKDI006121 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI006326 | Pathological Conditions, Signs and Symptoms | - | Congenital Abnormality | group | |
| TCMBANKDI006328 | - | Abnormality of the genitourinary system | Disease or Syndrome | phenotype | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI010445 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI014531 | Pathological Conditions, Signs and Symptoms; Neoplasms; Musculoskeletal Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI014839 | Nutritional and Metabolic Diseases; Immune System Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI016026 | Neoplasms; Eye Diseases | Neoplasm; Abnormality of the eye | Neoplastic Process | disease | |
| TCMBANKDI016890 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI018151 | Digestive System Diseases; Nutritional and Metabolic Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI018731 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI018837 | Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases | Abnormality of the immune system; Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI019452 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI020643 | Neoplasms; Infections; Immune System Diseases; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI020794 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI021339 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | group | |
| TCMBANKDI022727 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024968 | Digestive System Diseases; Nutritional and Metabolic Diseases | Abnormality of the digestive system | Pathologic Function | phenotype | |
| TCMBANKDI025141 | Endocrine System Diseases | Abnormality of the endocrine system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI028385 | - | - | Neoplastic Process | disease | |
| TCMBANKDI028799 | Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI029520 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI029791 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI029861 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031297 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI031381 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031438 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI031973 | Pathological Conditions, Signs and Symptoms; Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI032152 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI032472 | Pathological Conditions, Signs and Symptoms; Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI032496 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI032498 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab